Journal
INTERNATIONAL REVIEWS OF IMMUNOLOGY
Volume 28, Issue 1-2, Pages 49-68Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/08830180802495605
Keywords
vaccine development; HIV; multi-envelope; DNA-vaccinia virus-protein
Categories
Funding
- NIH NIAID [P01-AI45142]
- NIH NCI [P30-CA21765]
- Federated Department Stores
- Mitchell Fund
- Pendleton Fund, the Pioneer Fund and the American Lebanese Syrian-Associated Charities (ALSAC)
- NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI045142] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The human immune system has evolved to recognize antigenic diversity, a strength that has been harnessed by vaccine developers to combat numerous pathogens (e.g., pneumococcus, influenza virus, rotavirus). In each case, vaccine cocktails were formulated to include antigenic variants of the target. To combat HIV-1 diversity, we assembled a cocktail vaccine comprising dozens of envelopes, delivered as recombinant DNA, vaccinia virus, and protein for testing in a clinical trial. One vaccinee has now completed vaccinations with no serious adverse events. Preliminary analyses demonstrate early proof-of-principle that a multi-envelope vaccine can elicit neutralizing antibody responses toward heterologous HIV-1 in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available